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Degenerative aortic stenosis is the most frequent valvular heart disease in industrialized countries. 
Conservative treatment may beneficially influence symptoms but is never successful. Surgical aortic valve 
replacement (SAVR) was the only recognized treatment option to provide substantially prolonged survival 
until 2008. Operative mortality of isolated SAVR has been reported as low as 0.5% to 1% in experienced 
institutions, while long-term survival is close to that observed in a control healthy population of similar 
age. A multitude of studies have demonstrated the beneficial effects of SAVR with regard to improvement 
in quality of life and physical performance in the majority of symptomatic patients. In the last decade, 
transcatheter aortic valve implantation (TAVI) has emerged as an equal treatment modality, first in patients 
with high surgical risk and more recently in patients with intermediate and low surgical risk. Paravalvular 
regurgitation and the higher rate of pacemaker implantation remain points of consideration. Additionally, the 
long-term durability of TAVI devices and occurrence of stroke late after TAVI require additional analyses. 
Sutureless (SU-SAVR) and rapid deployment valve (R-SAVR) were designed to simplify and accelerate a 
conventional or less invasive surgical procedure while allowing complete excision of the calcified native 
valve. From 3 different implants tested more than 10 to 15 years ago, only two are available on the market 
today: the Perceval® valve from Liva Nova and the Intuity® sutureless prosthesis from Edwards Lifesciences. 
There has been extensive experience with these two devices in previous years and the results obtained are 
comparable to those observed following the use of conventional implants. The sutureless devices may be 
of particular interest for more complex and combined surgical procedures. This review summarizes the 
sutureless (SU-SAVR) and rapid deployment valve technologies and presents a clinical outlook for the patient 
population managed with these devices.
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Keynote Lecture Series
Treatment of valvular aortic stenosis
Aortic stenosis is the most common heart valve disease 
in industrialized countries. The disease is caused by 
progressive calcification of the valve leaflets and not 
infrequently of the valvular annulus during a later phase. The 
degeneration leads to an increased pressure load on the left 
ventricle. If left untreated, aortic stenosis may have a similar 
prognosis to different types of cancer, with a life expectancy 
between 2 and 4 years, depending on the severity of the 
symptoms. Demographic studies have demonstrated that 
the prevalence of aortic valve stenosis is between 2–10% 
of the population aged older than 65 (1,2). The second 
most frequent etiology is congenital stenosis, commonly 
associated with bicuspid anatomy, whilst rheumatic disease 
is still substantially causative in developing nations.
Echocardiography is the most important investigative 
tool used to confirm the diagnosis and the severity of aortic 
stenosis, once suspected by clinical examination and a 
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precise description of the valve morphology is required. In 
addition, information on the size and the function of the 
left ventricle, the severity of hypertrophy (i.e., inclusively 
a localized, asymmetric septal hypertrophy that would 
require resection) and the size of the aortic root may be 
generated through transthoracic echocardiography. Current 
guidelines recommend aortic valve replacement as soon as 
the valve area is below 1.0 cm2 and the mean transvalvular 
pressure gradient is higher than 40–50 mmHg (3). More 
recently, low-flow low-gradient aortic stenosis has been 
recognized as an established indication for replacement 
therapy as well. CT or magnetic resonance imaging allows 
a complete evaluation of the dimensions of the thoracic 
aorta (i.e., aortic root, ascending aorta and aortic arch), 
the diagnosis of calcifications (i.e., none, mild or porcelain 
aorta) as well as the precise anatomic location in the 
thorax to optimally prepare less invasive approaches and/
or to evaluate the suitability of a retrograde transaortic 
access for transcatheter aortic valve implantation (TAVI). 
Invasive transvalvular pressure recording and hemodynamic 
assessment, including pulmonary pressure, are performed 
during cardiac catheterization while coronary angiography 
is required in patients above 40 (men) or 50 (women) to 
exclude coronary artery disease.
The current indications for aortic valve replacement as 
well as the evidence for this therapeutic option have been 
summarized in the most recent Guidelines of the European 
Society of Cardiology-European Association of Cardio-
thoracic Surgery. All symptomatic patients with severe 
aortic stenosis should receive either SAVR or TAVI (3).
Surgical aortic valve replacement (SAVR) is one of the 
most frequent cardiac procedures and a definitive therapy 
that considerably improves symptoms and long-term 
survival; the procedure has been the gold standard for 
more than 50 years and the operative mortality has been 
described as low as 0.5% to 1% in experienced institutions, 
with promising long-term outcomes (4,5). Other variables, 
such as age, gender, emergency operation, decreased left-
ventricular function, high blood pressure, coexisting 
coronary disease and reintervention procedures, may 
adversely influence the perioperative mortality. In these 
patients, TAVI has developed as an attractive alternative to 
SAVR in the last decade and will play an increasing role in 
the future. Sutureless rapid deployment valve prostheses are 
fabricated with a similar concept to TAVI but the role of 
these implants has still to be clarified.
Long-term survival after SAVR is comparable to that 
seen in a similar-age control population (5,6). An improved 
subjective quality of life, a rise in physical performance 
and the significant increase in survival are classical benefits 
following surgery. If SAVR is needed, the selection of the 
optimal implant is crucial. Although mechanical valves are 
much longer lasting, a substantial proportion of the patients 
would prefer an option without life-long oral anticoagulation. 
This is exactly the major advantage of tissue valves, at the 
price of a “non-permanent” option, since tissue valves will 
degenerate after a certain period of time (i.e., depending 
on the age of the patient at implantation). Stentless and 
sutureless aortic valves were introduced with the hope of 
favourably influencing the rate of degeneration and/or to 
improving hemodynamic properties (e.g., lower transvalvular 
pressure gradients) compared to those of conventional valves.
Since 2008, TAVI has been demonstrated to be 
technically feasible and successful in a large proportion 
of patients, starting with older patients and with those 
presenting with a high surgical risk. Nowadays, TAVI is 
offered to the whole population that needs a tissue valve, 
meaning an increasingly younger and low-risk patient 
population (7-9). Even though the results have become 
similar to those obtained with SAVR, some concerns remain 
regarding the incidence and the severity of paravalvular 
regurgitation and the higher rate of pacemaker requirement. 
In addition, there are no comparable series of long-term 
results as there are for surgical tissue valves; therefore, the 
estimation of long-term durability remains scarce (10-14). 
Finally, some concerns have been raised regarding the long-
term occurrence of stroke after TAVI.
Current guidelines are increasingly permissive for 
TAVI (6,13). This means that results of SAVR must still 
be improved to keep competitive with those of TAVI. One 
way to fulfil this accomplishment may be obtained with the 
use of sutureless and rapid deployment valves. This might 
be of particular interest for specific conditions (e.g., less 
invasive solutions and complicated cases, such as mixed and 
therefore lengthy procedures) (15-17).
The history of heart valve, with special reference 
to sutureless valves
In 1954, Hufnagel and his collaborators identified 23 
patients with a pure aortic regurgitation. At the time, the 
treatment offered consisted of expedient implantation of an 
acrylic ball valve into the descending aorta (18). As the valve 
blocked backward flow from the low part of the body only, 
the beneficial effect on heart function was limited. In 1961, 
Starr implanted the first mechanical heart valve—a caged ball 
377Annals of cardiothoracic surgery, Vol 9, No 5 September 2020
© Annals of Cardiothoracic Surgery. All rights reserved. Ann Cardiothorac Surg 2020;9(5):375-385 | http://dx.doi.org/10.21037/acs-2020-surd-18
designed valve—in a patient with mitral valve disease (19).
Researchers understood that an optimal cardiac valve 
device should be biocompatible, atraumatic for the blood 
flow and the blood cells and non-thrombogenic. Despite 
significant advances in technology, there are still no ideal 
valve replacement devices on the market. Both prosthetic 
implants (i.e., the mechanical and tissue valves) have certain 
benefits, but they also have numerous disadvantages. 
While mechanical valves provide long-term structural 
stability, they require long-term anticoagulation and the 
noise perceived by the patients may be disturbing (20,21). 
In comparison, tissue valves mimic the normal blood flow 
through a native valve, are made of a biocompatible material 
(e.g., xeno-pericardial tissue) and do not require long-term 
anticoagulation. All these devices are subjected to micro-
destructive weakening of the valve over time (22).
Looking at the hemodynamics observed in conventional 
mechanical carbon valve devices, the non-physiologic 
closing of these bi-leaflet prostheses constitutes an 
imperative to look for a new tri-leaflet valve design (23). 
Advanced experimental, numerical and biomolecular blood 
flow analyses have shown that the reverse flow rather than 
the forward phase is responsible for platelet activation 
and micro-thrombus formation. These details have been 
widely overlooked and the surgical community still believes 
that cumadines are necessary following mechanical valve 
replacement because of the organic material that is exposed 
to the blood flow.
The actual interest is focused on the design of a new tri-
leaflet valve that would be much more similar to that of a 
biological valve than a bi-leaflet valve in term of transvalvular 
blood flow. Such a valve combines the optimal hemodynamics 
of tissue valves with the durability of a mechanical one. In 
addition, computational modeling shows that this valve 
design closes much slower than a conventional bi-leaflet 
valve, quite similar to a tissue valve. Based on industrial 
design, the long-term durability of such a valve is quite 
predictable and that may challenge TAVI devices.
Between the classical surgical prostheses and the TAVI 
devices, sutureless and rapid deployment valves can be 
considered as a pertinent alternative that allows for quick 
placement into the aortic annulus via a surgical approach 
but without a sewing requirement (15,16,24).
Preliminary experience with sutureless valves, 
starting 2008
Reports on experimental and clinical studies with sutureless 
valves have been already published in the early sixties, with 
the intention to promote easier implantation and shortening 
ischemic and perfusion times (25). This concept was 
ultimately not pursued because of various complications, 
including paravalvular leakage and thrombotic deposits 
on the device with subsequent peripheral embolization. 
Interestingly, the concepts for a sutureless device had 
a revival approximatively 20 years ago with the first 
prototypes being tested in animal experimentation. Parallel 
to these developments, the first concepts for transcatheter 
aortic valve technology were developed simultaneously. 
Both concepts were quite similar; one of the main 
characteristics of these new devices being the possibility to 
crimp them for the introduction into the definitive position.
Even though isolated SAVR is a technically simple 
procedure, there are considerable differences regarding 
the overall time needed for this intervention, including 
large differences in ischemic and perfusion times. One 
of the major features of sutureless valves was to make 
the procedure more reproducible, for instance, with less 
differences between very short and very long cross-clamp 
times, accelerating surgery but also allowing for a more 
stable fixation of the valve into the native anulus when a less 
invasive approach has been chosen and the accessibility for 
the classical fixation stitches may be compromised (26-28). 
In addition, one considerable advantage of sutureless 
valves is that, contrary to TAVI, the heavily calcified 
valve is completely excised; the latter condition may 
have at least a theoretically beneficial effect on the rate 
of subsequent prosthetic endocarditis. Three different 
sutureless prostheses received CE market approval: the 3f 
Enable® valve from ATS, later Medtronic, the Perceval 
S® from Sorin, later Liva Nova and the Intuity® sutureless 
prosthesis from Edwards. Today, only the Perceval and the 
Intuity valves are still on the market, the 3-f Enable has 
been retired in 2014 most probably because of an increased 
risk of migration. At that time, the tool available for the 
loading and deployment of the Enable valve was rather 
uncomfortable. In the following, we will briefly present the 
3 different devices that were developed for clinical use with 
a focus on the two that are still on the market today.
The Enable valve from ATS-Medtronic
The Enable valve concept originated from the combination 
of the 3f tubular stentless valve (Figure 1) with a nitinol 
stent that had the properties of being crimped without 
damage to the stent while the latter returned to its original 
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Figure 1 Tubular structure of the stentless 3-f aortic tissue valve.
Figure 2 The sutureless 3f Enable® Aortic Bioprosthesis Model 
6000.
Figure 3 ATS 3f Enable® Aortic Bioprosthesis Model 6000, 
Modified Frame.
shape at normal temperature. The original stentless 3-f 
valve was designed to replicate the natural aortic valve’s 
physiological function, according to the principle that form 
follows function (27).
The 3-f valve was made of three similar segments of 
equine glutaraldehyde-fixed xeno-pericardial tissue. The 
cranial portion of the valve had three tabs reinforced 
through a small fabric piece each that had to be fixed to 
the aortic wall as neo-commissures to stabilize the leaflets. 
Systematic pre-clinical tests of 3f Aortic Bioprosthesis 
Model 1000 (the original stentless model) were carried out 
under the Food and Drug Administration (FDA) and the 
ISO Guidance. Together with widely deployed stentless 
and stented valves control measures, the in vitro and in 
vivo results were favourable. This valve was implanted 
in 165 patients as part of a worldwide, multicenter, non-
randomized study. During the entire study duration, there 
was no prosthetic degeneration nor valve thrombosis. After 
a five-year follow-up interval, the overall freedom from 
valve mortality was 98.5 percent (27).
Enable I and II device description
The 3f Enable® Aortic Bioprosthesis System 6000 was built 
from the stentless valve 3f and incorporated the tissue valve 
into a self-expanding Nitinol stent (Figure 2).
The Model 6000 design of the valve leaflets was identical 
to Model 1000 (Figure 3). The extended Nitinol structure 
(polyester fabric to cover the inflow flange)
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contributed, thanks to externally induced radial factors 
embedded in the NiTiNOL component, to the stabilization 
of the unit in the angular position used. The polyester fabric 
surrounding the inflow contributed to a stable fixation at 
the level of the aortic annulus and the proximal portion 
of the aortic root. Similar to the development of TAVI 
devices, the polyester bridge of the Enable valve was added 
to the original design to mitigate perivalvular leakage and 
the danger of migration. The main difference between the 
initial and the updated versions were: size of the polyester 
fabric to increase the sealing properties within the aortic 
structures and the fact that the new frame was constructed 
to be crimped and not folded, allowing a circumferential 
deployment comparable to transcatheter valves.
Our institutional experience with this model was very 
favourable. We implanted this valve in 28 patients (mean 
age of 75.7±6.6 years, Euro-Score of 7.1±1.7). Due to 
cautious handling and the obligatory learning curve, the 
duration of cross-clamping and total perfusion times was 
not substantially shorter than those of isolated SAVR. 
The preliminary experience was satisfying without major 
perioperative complications (i.e., migration, obstruction 
of coronary ostia, interference with the mitral valve or 
traumatic injury of the ascending aorta) (28-30).
Transvalvular pressure gradients were comparable 
to those of stentless valves (mean 6.1±2.6 mmHg, peak 
18±5 mmHg). Five patients (18.5%) received permanent 
pacemaker implantation. Although the results were 
promising, Medtronic issued a field safety notice in 
November 2014 to alert physicians to the risk of migration 
with the 3f Enable Aortic Bioprosthesis (Model 6000) 
and to modify the instructions for use to recommend the 
use of two tied off guiding sutures. Since the issuance, 
the company did not receive any new reports of 3f 
Enable Aortic Bioprosthesis migration. While the revised 
instructions in the field safety notice continued to show 
positive outcomes, the product had seen limited commercial 
adoption. Therefore, Medtronic decided to discontinue the 
3f Enable Aortic Bioprosthesis (Model 6000) and the related 
accessories in May 2015 (31). We tried to find additional 
reasons for this. In fact, there were probably multiple: 
marginal teaching during the very initial experience, 
uncomfortable deployment using a cumbersome folding 
tool and finally the concurrential situation played by TAVI, 
that was in full development at that time.
The Perceval S sutureless valve
Perceval S is a sutureless aortic valve prosthesis made of 
bovine tissue pericardium attached to an automated anchor 
that is used to stabilize and fasten the implantation site 
(Figure 4). The configuration of the anchoring system 
consists of two segments (called the outflow and inflow 
rings), three valve-supporting elements and three sinusoidal 
elements that are positioned in the Valsalva sinuses (32).
The alloy used for the anchoring system is a Nickel/
Titanium equiatomic compound called Nitinol, capable of 
carrying large recoverable deformations (about 8–10 times 
the strength of the steel) and recovering its initial design 
when stress is removed (super elastic impact driven by 
deformation). The Perceval S prothesis can therefore be 
compressed for implantation and eventually reached its final 
diameter as soon as released.
The device is coated with a thin, turbostratic carbon film 
CarbofilmTM that improves haemo- and biocompatibility. 
The material is designed as every other pericardial valve: the 
scientifically validated valve configuration is equipped with 
a pericardial screw cap, which facilitates tolerance to the 
aortic annulus and avoids paravalvular leakage. A buttonhole 
placed at the level of the inflow assists the placement 
of the prothesis in relation to each valve sinus avoiding 
malrotation during inflation. A scientifically verified 
glutaraldehyde fixation cycle supported by the patented 
neutralization procedure for aldehyde compounds allows 
immediate implantation without rinsing, therefore making 
the time interval between unpacking and deployment 
very short. Perceval S foldable twin ended sizers aid the 
surgeon to select the best possible size of the prothesis: 
their construction allows identification of the annulus, 
even in complicated anatomy. Dedicated instruments assist 
Figure 4 Sutureless Perceval tissue valve.
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the implantation of the Perceval S valve: crimping device, 
manometer and expansion balloon (Figure 5). The size 
of the prosthesis is gradually reduced to a reasonable size 
before implantation with the Perceval S collapsing device 
and then placed onto the Perceval S frame (Figure 5). After 
introduction within the aortic anulus, the valve is opened 
in two phases: first the inflow ring is extracted at the level 
of the annulus and then the complete prosthesis release 
is performed when the surgeon can confirm the exact 
positioning (Figure 6). The post-dilatation ballon catheter 
is inserted into the prosthesis to optimize the position by 
forming the framework against the annulus at the inflow 
stage after insertion of the Perceval S (Figure 7).
The Perceval S prothesis was evaluated in three early 
phase clinical studies:
(I) The “PERCEVAL TRIAL—Perceval S valve pilot 
Figure 7 Final step of the implantation: dilatation of the Perceval 
S valve into the aortic annulus.
Figure 5 Valve to be crimped (A) and ready for implantation (B).
Figure 6 The guiding stitches are passed through the corresponding loops present at the external aspect of the inflow ring (A). The valve 
has been parachuted into position (B).
A B
A B
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trial—V10601”;
(II) The “PERCEVAL Pivotal Trial—V10801”;
(III) The “CAVALIER—Perceval S valve clinical trial 
for extended CE mark—TPS001”.
The first investigations were performed in 30 high-
risk patients who were scheduled for isolated aortic valve 
replacement because of severe stenosis. This prospective 
analysis was undertaken at 3 European Centers from 
April 2007 to February 2008 (27) and concentrated on 
perioperative and one-year outcome. Patients enrolled for 
this study would be typical TAVI candidates in the classic 
setting. They had elevated risk for surgery (age 75 years 
and above, functional class NYHA III and IV, Logistic 
EuroSCORE >5%). Operative mortality was 3.3%, 1 of 30. 
During a mean follow-up of 12 months, there was no valve 
dislocation, but two patients had moderate paravalvular 
leaks (27-33).
According to the outcome of this pilot study, the Sorin 
Company planned the “PERCEVAL Pivotal Study–
V10801” to support feasibility and efficiency in a larger 
cohort of patients. Between January 2009 and January 2010, 
150 patients were studied in nine European institutions. 
The main goal was to assess the feasibility and the clinical 
performance of the Perceval S prothesis at 3–6 months. The 
main aspects of the analysis were the change in clinical status 
and the hemodynamic performance of the implant. In a third 
step, the CAVALIER trial intended to determine Perceval 
S valve safety and efficiency in older patients (>65 years) 
and with more valve sizes available (21, 23, 25 mm). The 
primary goal was to determine the safety and effectiveness 
of the Perceval S valve in the first 12 months. The research 
started in February 2010 with an overall number of patients 
exceeding 600 among 25 institutions (34). The 30-day 
results showed that the Perceval valve was safe (favourable 
haemodynamic effect and low complication rate), and may 
be recommended for SAVR since the technique is fast and 
reproducible after a short learning period.
In conclusion, the Perceval S sutureless bioprosthesis 
is easy-to-use and has a low-profile interface; the results 
seem to be reproducible as they were comparable among 
all centers included into the different trials. A special 
advantage of the device is that its deployment in a narrowed 
and/or calcified aortic root can be achieved quickly after a 
short learning curve. After adequate teaching, the Perceval 
S Device may reduce the aortic cross-clamp time by 
approximatively 50 percent, with the shorter clamping time 
being about 15 to 18 minutes. A special indication could 
be the valve replacement in a degenerated homograft or in 
a degenerated porcine xenograft aortic root with circular 
wall calcification (35,36). In this case, incision to enter into 
the aorta may be performed distally to the homograft. The 
length of the deployment device is long enough to reach the 
annulus of the homograft and safely fix the valve.
The Intuity valve from Edwards Lifesciences
This is the third sutureless valve device that was developed 
through Edwards Lifesciences.  The valve system 
provides an innovative extended balloon structure for fast 
deployment. Anti-degeneration treatment includes the 
Thermafix method that is close to that used for the stented 
Perimount valve series by the same company. The Intuity® 
valve includes a widely spread polyester sealing cloth at 
the stage and just below the aortic valve anulus, covering 
the stainless-steel frame of the ballon (Figure 8). The 
specification includes Edwards Magna Ease technology 
(Edwards Lifesciences), which has proven sustained 
reliability and the SAPIEN transcatheter valve technology 
from Edwards (37,38). The valve received CE market in 
February 2012.
Six European hospitals recruited 152 consecutive 
patients who required surgical aortic valve substitution in 
the prospective TRITON single-arm research study (37). 
The hemodynamic performance of this valve was very 
encouraging: average EOA and gradients at 3 months were 
1.7±0.1 cm2 and 8.4±0.7 mmHg, with no changes at one-
year follow-up. Paravalvular leaks had a low incidence. The 
survival rate was at 98.6% at 30 days and 94% at one-year.
As for the Perceval S device, data on Intuity sutureless 
valves also revealed faster procedures characterized by 
shorter cross-clamp and cardiopulmonary bypass times. The 
aortic cross clamp times for simple aortic valve procedures 
Figure 8 The intuity sutureless valve (courtesy from Edwards).
Bovine pericardium and
ThermaFix process
Tri-leaflet matched for
thickness and elasticity
Polyester sealing cloth Balloon-expandable
stainless steel frame
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decreased by 48% and average bypass times by 39% 
compared to times reported in the adult cardiac database 
of the Society of Thoracic Surgeons (37-39). Due to the 
excellent results obtained with the two devices still available 
on the market, a substantial number of surgeons now use 
one of these 2 devices for minimal-invasive approaches 
(upper sternotomy and lateral thoracotomy).
Current clinical perspective
In the current era, cardiac surgeons are challenged through 
the rapid growth of transcatheter aortic valve implantation 
(TAVI) cases. To ensure the continued existence of the 
golden standard of SAVR, at least for those for whom a 
TAVI is not indicated, the outcomes still may be further 
improved. One of the main objectives is to mitigate surgical 
damage and establish new concepts for valve devices and 
new methods for surgical valve replacement. To define 
the benefit of sutureless and rapid deployment valves in 
current minimally invasive approaches in isolated aortic 
valve replacement, a panel of 28 international experts 
with expertise in both minimally invasive aortic valve 
replacement and rapid deployment valves was constituted. 
After thorough literature review, the experts rated evidence-
based recommendations but no guidelines could be 
established (40).
Different studies have been performed on sutureless 
aortic valves (SU-SAVR) or rapid deployment of aortic 
valves (R-SAVR) (41-45). In terms of clinical and 
hemodynamic behaviour, both valves seem very comparable 
and appropriate for the majority of procedures. Certain 
circumstances contribute to the choice of one over the 
other. In particular, when SAVR is planned through a less 
invasive approach, the Perceval-S valve may be a safer 
choice, since it folds on the holder systems and the view 
of the aortic annulus is optimized during implantation; 
however, the implantation of the Perceval-S requires a more 
cranial horizontal aortotomy that makes a concomitant 
replacement of the ascending aorta more complex. After 
implantation of the Intuity valve, transvalvular gradients are 
the lowest. All studies confirm the two major advantages: 
reducing surgical times and simplifying minimally invasive 
methods. The careful differentiation between R-SAVR and 
SU-SAVR is needed in clinical practice for the assessment 
of the outcomes, since both valve types vary significantly in 
structure and technique of implants.
While both valves are scientifically and hemodynamically 
comparable and are ideal replacement devices for the 
majority of patients, there are few conditions where one 
device may be better appropriated than the other. In fact, 
the Perceval-S valve can be more suited during less invasive 
SAVR through right anterior thoracotomy, because it is 
collapsible in the holder, thus giving maximal visibility to 
optimally position and deploy the device into the aortic 
annulus. Nonetheless, Perceval-S implant requires a 
more cranial transverse aortotomy which makes radical 
supracoronary repair of the ascending aorta more difficult.
The average rates  of  postoperat ive pacemaker 
implantation (PPI) following TAVI have been around 
approximately 15–25%, with significant difference 
according to the type of TAVI device (46-49). Early PPI 
estimates were found to be as low as 3.0 percent following 
conventional sutured SAVR (50). The SU-SAVR and 
R-SAVR anchoring systems are comparable to transcatheter 
devices; as a consequence, patients are at increased risk of 
atrioventricular block postoperatively (51). The SU-SAVR 
nitinol stent and the expandable R-SAVR skirt contribute 
to higher tension in the left ventricular outflow tract and 
thus ultimately to atrioventricular conduction tissue. PPI is 
at 4.6% in the SU-SAVR group and 6.2% in the R-SAVR 
group with no clinically relevant difference (15). The rate 
of permanent pacemaker is considerably higher than those 
observed following standard SAVR prosthesis.
A new meta-analysis found an increased rate of PPI 
in patients with SU-SAVR valves (7.9%) compared to 
traditional SAVR implants (3.1%) (46). The differences 
reported in the rates of PPIs need to be carefully interpreted: 
the devices demonstrate large variations on the depth of the 
valve into the outflow tract. In addition, the sizing of the 
valve often becomes crucial, and “learning” surgeons tend 
to over-size the valve to prevent leakages, which can lead to 
higher radial pressure across the subvalvular rim. Regarding 
the hemodynamic benefits, results reported in the literature 
are somewhat controversial. The R-SAVR displayed lower 
average peak and mean gradients, this has been confirmed 
by a direct comparison with SU-SAVR (15). Absolute figures 
indicate only a small gap between the two systems. A newer 
study comprising INTU-ITA data alone indicates that peak 
and average gradients remain constant until four years after 
implantation (42).
Outlook and take-home message
In this short overview, we have tried to summarize the 
historical evolution of the introduction of sutureless 
valves alongside the introduction of TAVI. The following 
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chapters will present in depth clinical experience with larger 
cooperative studies between expert institutions. There has 
been several platforms reporting the results of sutureless 
valve devices. A comprehensive clinical data report on safety, 
effectiveness and hemodynamic efficiency was developed 
in 2014 under the auspices of the International Valvular 
Surgery Study Group. It consisted of 36 cardiac surgeons 
from 27 major centers worldwide. The projects included 
historical as well as potential trials of the International SU-
AVR registry which have been reported in recent years 
(40,52).
The subsequent technical advances in aortic valve 
replacement (SAVR) with R-SAVR and SU-SAVR push the 
surgeons to further ameliorate their own results: shorter 
crossclamp and CPB times and an increase in the rate of 
minimal invasive procedures. Both systems demonstrated 
comparable, promising results in terms of hemodynamic 
efficiency, reliability and safety. The implantation technique 
requires specialized instruction for the first 5 to 10 cases 
while in some institutions the incidence of PPI remains a 
concern. SU-SAVR and R-SAVR have helped to further 
improve the results of SAVR in different subsets of patients 
(53,54); this procedure is competitive with TAVI. The 
diversity of the observed benefits is underreported and thus 
it will be important to confirm beneficial results by long-
term examinations of detailed data collection.
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